Prothena Corporation plc Stock News

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that it will report its 4th quarter and full year 2023 financial results on February 15, 2024 after close of U.S. financial markets.

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.97 per share a year ago.

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro

Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data from its highly anticipated Phase 1 Alzheimer's Dis

Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter.

Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently